New initiative to study Parkinson disease

Su-Chun Zhang, MD, PhD, the Steenbock Professor in Behavioral and Neural Sciences at the University of Wisconsin-Madison and Waisman Center investigator, is part of an interdisciplinary team of researchers selected by the Aligning Science Across Parkinson’s (ASAP) initiative to receive $9 million over three years for the “Parkinson5D: Deconstructing Proximal Disease Mechanisms Across Cells, Space and Progression” or PD5D project.

Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug

Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.

UW–Madison’s EdNeuroLab tackling math learning through brain imaging

In 2012, Edward Hubbard, a cognitive neuroscientist and assistant professor with UW‒Madison’s Department of Educational Psychology, created the Educational Neuroscience Lab to understand — through functional magnetic resonance imaging (fMRI) — how the physical changes that occur in children’s brains as they learn may help improve education practices.

Improved technique illuminates fragile X protein

Researchers at the Waisman Center made a significant step in understanding the function of a specific protein, FMR1, whose absence causes fragile X syndrome, or FXS. Waisman investigators Xinyu Zhao, PhD, and Anita Bhattacharyya, PhD, with research associate Meng Li, published their paper “Identification of FMR1-regulated molecular networks in human neurodevelopment” in the March issue of the journal Genome Research.